Several cutaneous paradoxical reactions have been reported in association with IL-17 inhibitors, such as eczema, sarcoidosis-like eruptions, alopecia areata (AA), pyoderma gangrenosum (PG), vitiligo, bullous pemphigoid, and pemphigus vulgaris. This evidence concerns the gene IL17A and vitiligo.